吉利德赢得加州最高法院“创新义务”诉讼裁决

The California Supreme Court on Monday ruled in favor of Gilead Sciences (GILD) in a case that tested whether drugmakers are obligated to develop safer drugs.
Gilead was facing claims from more than 24,000 individuals who were using one of its HIV medications and accused the biopharma of abandoning work on another drug that had fewer side effects.
The drug the patients were taking was Viread (tenofovir disoproxil fumarate), which has a boxed warning on potential impacts on kidney function and a standard warning on bone density.
Development of the alternate treatment, tenofovir alafenamide fumarate, ended in 2004. However, Gilead later resurrected development of it as a hepatitis B therapy, and it was approved as Vemlidy in 2015.
"What today’s decision declines to do is recognize, for the first time anywhere, sweeping liability for injuries caused by a concededly nondefective drug because the manufacturer allegedly failed to make a different drug available sooner," Justice Joshua Groban wrote in the majority opinion. "Imposing such liability would create substantial burdens and would risk adverse consequences for pharmaceutical innovation, public health, and patient safety."
"The California Supreme Court's decision supports American innovation, allowing companies to continue pursuing breakthroughs for patients and consumers," Gilead said in a statement to Reuters.